Dr. Leroy Hood is a world-renowned scientist and recipient of the National Medal of Science (2011). He co-founded the Institute for Systems Biology (ISB) in 2000 and served as its first President until 2017. Dr. Hood is a member of all three National Academies: Sciences, Engineering, and Medicine—one of only 20 people worldwide with this distinction.
With an MD from Johns Hopkins and a PhD from Caltech, Dr. Hood was a Caltech faculty member for 25 years, chairing the Biology Department and developing instruments critical to the Human Genome Project. He later founded the Department of Molecular Biotechnology at the University of Washington.
Dr. Hood’s research focuses on Alzheimer’s, cancer, and wellness, including a pioneering 1 million patient genome/phenome project. He has co-founded 15 biotechnology companies, including Amgen and Applied Biosystems, and has published over 850 peer-reviewed articles with 36 patents.
His numerous awards include the Lasker Award (1987), the Kyoto Prize (2002), and the Fritz J. and Delores H. Russ Prize (2011)

Director of Systems Biology

Dexter Hadley, MD,PhD is a physician-scientist and AI researcher advancing precision medicine through AI and big data. As Director of AI in Precision Medicine at ABOPM, he drives initiatives in clinical decision support and biomarker discovery. He earned his MD and PhD in Genomics and Computational Biology from the University of Pennsylvania and completed a Clinical Pathology residency at Stanford University. He developed an Investigational New Drug (IND) that was approved for an ADHD therapeutic and has led NIH-funded projects, including: STARGEO.org – an open-source biomarker discovery platform, CrADLe (Crowd-Assisted Deep Learning) Digital Curation – translating big data into precision medicine, and MammoChat.com – an AI-powered platform improving breast cancer outcomes. As Chief of AI at UCF College of Medicine, he collaborates with AdventHealth and the Orlando VA to implement AI solutions in healthcare. Committed to fair AI applications, he develops bias-correcting algorithms and fairness-aware datasets to ensure accessibility and inclusivity. His work continues to integrate AI into clinical workflows, enhancing patient outcomes.

Director of AI in Precision Medicine

Dr. Tyler Panzner, PhD, is a pharmacologist on a mission to modernize medicine by bringing nutraceutical safety, genetic personalization, and pharmacological rigor to the forefront of health optimization.
His education includes a Bachelor of Science in Cellular & Molecular Biology from the University of South Florida and a Ph.D. in Molecular & Cellular Pharmacology from Stony Brook University. His research focused on extracellular vesicles and their role in breast cancer metastasis and tumor-immune crosstalk. It was during his graduate training that he had his genome sequenced and through his own analysis was able to resolve numerous of his chronic health issues through targeted nutrition, nutraceutical, and lifestyle modifications.
He then founded Holistic Genetic Health Solutions, a precision-wellness consultancy to help provide others with the same genomic-driven transformation that had given himself by converting genomic, laboratory, and lifestyle data into actionable protocols.
Along his journey of genetically optimizing the health of hundreds over the past 3 years he's observed a recurrent problem—people harmed by inappropriate nutraceutical usage. In most cases the injuries can be traced to interactions between nutraceuticals and (1) an individual's genetic profile, (2) other nutraceuticals, (3) foods, or (4) prescription medications. This isn't just from consumers choosing the wrong products on their own accord, but often through guidance by healthcare professionals as well that lack pharmacology knowledge.
In a world where people want "evidence-based" medicine, Dr. Panzner often highlights how there is a massive lack of studies on nutraceuticals and their various interactions. To fill this knowledge gap, he established a robust social media presence to educate about safe supplementation and help others navigate the overwhelming (and often contradictory) supplement space at scale. His combined social media channels now exceed 3 million monthly viewers, and his trademark short form video content translates nuanced pharmacology into concise, yet clinically relevant guidance for both practitioners and the public.
Whether you're a medical professional prescribing medications, a health coach recommending supplements, a nutritionist providing dietary guidance, or someone scrolling social media looking for actionable health tips, his mission is simple: to establish rigorous, personalized, and safe use of these consumables as a standard component of modern pharmacology and functional medicine.
Outside of work, Dr. Panzner enjoys the beach, fitness, and DJ'ing electronic music.

Director of Functional Genomics & Pharmacology

Dr. Varun B. Dwaraka is a computational and bioinformatics scientist with profound expertise in ageing, epigenetics, and biomarker identification. As the Head of Bioinformatics at TruDiagnostic, he leads a dedicated team developing advanced machine-learning models to uncover epigenetic biomarkers, focusing on understanding molecular ageing and its associations with disease and mortality risk. Dr. Dwaraka’s work integrates multi-omic data, incorporating metabolic, proteomic, phenotypic, and DNA methylation measures, enabling him to establish novel age-predictive algorithms critical to advancing age-related research.
Dr. Dwaraka’s background includes a Ph.D. in Biology from the University of Kentucky, where he specialized in the genetic and epigenetic foundations of tissue regeneration in salamanders. His undergraduate training in Molecular, Cellular, and Developmental Biology from the University of California, Santa Cruz, focused on bioinformatics. Throughout his career, he has contributed to high-impact bioinformatics and multi-omic research initiatives at institutions such as UCSF and the Carnegie Institute of Science, and his insights have been widely recognized in leading journals like Nature Aging and Genome Medicine.
In addition to his research, Dr. Dwaraka is a Principal Investigator at TruDiagnostic, spearheading scientific projects that have attracted attention from prominent media outlets like Forbes, BBC, and Men’s Health. His contributions to popular documentaries on platforms like Netflix and HBO highlight the real-world implications of his research in public health and ageing. A full member of the Sigma Xi Scientific Research Honor Society and a 2023 Foresight Fellow in Biotechnology and Health Expansion, Dr. Dwaraka is an active voice in his field, presenting as an invited speaker at international conferences and prestigious academic gatherings.

Director of Epigenomics

Dr. Raghda Elsawi Eldesouki is a distinguished faculty member and researcher specializing in medical genomics, virology, and immunogenetics, with a career dedicated to advancing precision medicine. Her research journey began with mastering molecular techniques to develop therapeutic options against cancer stem cells, advancing to genome-wide association studies (GWAS) in Egyptian populations to explore genetic variations. Through genomic surveillance and next-generation sequencing (NGS) of SARS-CoV-2, she has investigated how viral and host factors contribute to clinical outcomes. To further enhance the impact of her research, Dr. Eldesouki current research is focusing on incorporating machine learning, to develop predictive models for clinical outcomes that integrate genetic and clinical data. This approach aims to support personalized treatment strategies for infectious, chronic diseases and cancers, ultimately reducing health disparities.
Dr. Eldesouki is an active member of multiple prestigious associations, including the American Society of Human Genetics, the American Association for Cancer Research, and the American Society of Microbiology, where she regularly contributes to the advancement of the field. She has also presented her research at high-profile conferences, such as the American Association for Cancer Research (AACR) Annual Meeting and the ASM Clinical Virology Symposium, where she has shared her findings on genomic surveillance and genetic markers in cancer.
In her role as Director of Medical Genomics at the American Board of Precision Medicine, Dr. Eldesouki continues to advocate for team-based learning integrated with a problem-based approach. She emphasizes collaborative learning, encouraging clinicians and students to work together to solve complex, real-world cases, enhancing critical thinking and clinical decision-making. This innovative approach is central to her teaching, helping learners connect foundational genetics knowledge to practical, precision medicine applications.
Outside of her professional pursuits, she enjoys jogging, cycling, swimming, and watching comic movies. Her active lifestyle fuels her commitment to advancing education and research, bringing cutting-edge genetic insights to the forefront of clinical practice.

Director of Medical Genomics

Dr. Paniz Jasbi, PhD, is a leading expert in metabolomics and personalized healthcare, with a background in systems biology and mass spectrometry from Arizona State University. As Co-Founder and Chief Science Officer of Theriome Inc., he helped develop the Aristotle Test, a key tool for advancing personalized care. Dr. Jasbi also serves as Director of Metabolomics at the American Board of Precision Medicine and has published extensively in top scientific journals. His work focuses on translating scientific discoveries into clinical applications to improve global health outcomes.

Director of Metabolomics

Alex Mohr, PhD, is the Director of Microbiomics at Theriome, where he spearheads initiatives that integrate multi-omics and systems biology approaches to advance precision medicine. As a co-founder of Theriome, Alex has been instrumental in pioneering research on the gut microbiome, leveraging bioinformatics and multi-omic analyses to illuminate the intricate relationships between microbiota, host metabolism, and health outcomes. His work emphasizes the potential of microbiome-based interventions to enhance individual resilience and inform therapeutic strategies.

Director of Microbiomics

Dr. Allie Greenplate is the Director of Strategic Alliance & Operations for Penn Medicine’s Institute for Immunology and Immune Health. She received her Ph.D. at Vanderbilt University in 2018 and performed postdoctoral research at the University of Pennsylvania from 2019-2020 under the mentorship of Dr. John Wherry. Dr. Greenplate has over a decade of experience in microbiology and immunology, with specific expertise in longitudinal immune monitoring, systems immunology, and computational immunology. She helped pioneer the use of mass cytometry for deep immune profiling of clinical samples to support clinical care.

Under Dr. Greenplate’s leadership, Immune Health has become a central hub for performing patient immune assays at the University of Pennsylvania and delivering results to clinicians. She built a team of over 25 staff, trainees, and faculty spanning 4 pillars. Together, they have enrolled, processed, and analyzed the immune systems of over 3,500 subjects, and generating over a dozen publications and one new test delivered to the electronic medical record.

Director of Molecular Immunology

Dr. Eric Van Gieson has over 25 years of experience in developing biotech and medtech with leadership roles industry, academia, and government. Currently, he is the CEO of EPOCH Epigenetics and also consults to use his skills in building partnerships with the U.S. Government and industry to ensure rapid transition of early-stage biomedical/biotechnology platforms to end users. Eric’s diverse roles include Chief Technology Officer at the National Strategic Research Institute (NSRI, a STRATCOM UARC) as well as Director of Biosurveillance and Diagnostics at MRIGlobal. At MRIGlobal and at NSRI, Dr. Van Gieson worked together with private and interagency partners to develop a novel patient transport system, known as the Containerized BioContainment System (CBCS). This platform ultimately received an R&D 100 award and is currently in use by the Department of State, Department of Defense, and has served critical roles in transport of civilian/military patients in both Ebola and COVID 19 outbreaks. He has also served as Chief of the Diagnostics, Disease Surveillance, and Threat Detection Division within the Defense Threat Reduction Agency (DTRA), and as Principal Professional Staff at the Johns Hopkins Applied Physics Laboratory (JHUAPL). In his spare time, Dr. Van Gieson has served as the Chief Judge on the Nokia Sensing XChallenge and a Judge on the QualComm Tricorder XChallenge on behalf of the XPrize Foundation. Most recently, he served for DARPA as a Program Manager, from 2017-2022, where he initiated programs to use host-based methods to mitigate the impacts of emerging diseases using host-based epigenetics, as well as to optimize human performance with multiomic methods. Through this work, he has enabled a new diagnostic paradigm to be created that harnesses the epigenome with AI/ML-based biological pathway analyses. This work has led to new technologies that can both diagnose and prognose diseases, guide healthcare decisions, optimize human performance, and enable discovery of new medical therapies based upon host pathway modulation. His other DARPA work has created technologies to prevent traumatic brain injury with molecular prophylaxes. Throughout his time in the U.S. Government, Eric has spent a significant part of his time at DARPA working to commercialize the technology emerging from his programs. These commercialization efforts have led to >$100M in commercial and private investment in DARPA technologies (companies including Novo Nordisc, Iota
BioSciences, GE Research, and SecondWave) to ensure transition to both commercial and public/military applications. Dr. Van Gieson received his Doctor of Philosophy degree in Biomedical Engineering and a Bachelor of Science degree in Chemical Engineering from the University of Virginia. He has worked in industry and government settings and has publications on topics ranging from genomic analysis to unmanned systems autonomy. In his spare time, he enjoys spending time with his family, wrenching on old cars, wing foiling, mountain biking, and snowboarding.

Director of Multi-omic Medicine

Dr. Gregory Nacarelli, ND, PhD, MS, CNS, CNGS is passionate about advancing the field of precision medicine by combining leading-edge data analysis techniques with integrative medicine. He aims to teach practitioners how to integrate multiomics into clinical practice for more precise diagnosis and treatment. He earned his Doctor of Naturopathic Medicine degree from Bastyr University and has a Master's degree in individualized genomics & health from Johns Hopkins University, and a PhD in healthcare genetics & genomics from Clemson University, his dissertation focusing on nutrigenomics, metabolomics and cardiovascular disease. Dr. Nacarelli is a precision health consultant with Theriome and Selfdecode. He currently sees clients for precision health consults while educating practitioners on integrating precision health and nutrigenomics into clinical practice.

Director of Nutrigenomics

Dr. Rob Fraser is an accomplished scientist, entrepreneur, and biotech innovator with a career spanning molecular diagnostics, drug discovery, regulatory science, and personalized medicine. He is the President, Chief Scientific Officer, and Co-founder of Molecular You Corporation, where he leads the scientific strategy and innovation behind the company’s groundbreaking multi-biomarker analytics platform. Previously serving as the founding CEO, Rob pioneered a cost-effective method to quantify hundreds of biomarkers from a single blood sample, integrated with a large language model to extract actionable insights from global scientific literature.
Dr. Fraser brings deep expertise in molecular biology, proteomics, and precision health. His scientific foundation was built through advanced training at the University of Alberta, Harvard Medical School, and postdoctoral fellowships at the Hospital for Sick Children in Toronto and IGBMC in Strasbourg, France. Over the course of his career, he has held senior research positions at Sanofi, Xenon, Neuromed, and CDRD, where he led numerous drug discovery and development initiatives.
In 2011, Dr. Fraser co-founded the Personalized Medicine Initiative (PMI) at the University of British Columbia alongside Prof. Pieter Cullis, establishing a vision for targeted healthcare solutions. This led to the formation of several innovative companies, including GenXys Health Care Systems, Mesentech Corporation, Contextual Genomics, and Microbiome Insights, each addressing critical challenges in precision prescribing, drug targeting, and early disease detection.
Rob is also a Co-founder and Director at Novobind, and has raised over $50 million in funding to support various health tech ventures. His work has consistently focused on translating scientific breakthroughs into clinically actionable tools that improve patient outcomes.
A former varsity swimmer and member of the Canadian National Water Polo Team, Rob continues to lead with passion and purpose, dedicating time to philanthropic initiatives and advancing the application of science to improve human health.

Director of Proteomic

I’m Dr. Mara Ivy Raden, PharmD, and I’m on a mission to redefine what it truly means to be healthy. My journey began in emergency rooms and intensive care units, where I witnessed firsthand how Western medicine excels at managing acute crises—yet often falls short in addressing the root causes of chronic illness. This realization, combined with my own search for solutions to chronic health challenges, led me to pursue advanced studies in environmental medicine, ozone therapy, and integrative healing approaches.
As the Chief Wellness Officer and Co-Founder of Raden Wellness and Intrinsic Wellness, I’ve dedicated my career to helping people take control of their health, reverse biological aging, and achieve lasting vitality. At Raden Wellness, I specialize in cutting-edge IV therapies, personalized wellness protocols, and regenerative treatments designed to enhance energy, longevity, and overall well-being. Through Intrinsic Wellness, I lead product development focused on optimizing the human microbiome—leveraging human-identical prebiotics and natural molecules to support gut health, immune function, and systemic balance.
My approach extends to a diverse range of individuals, from corporate executives seeking high-performance health strategies to families, seniors, and proactive individuals focused on longevity and disease prevention. I also work closely with patients battling chronic pain and complex health conditions, as well as elite athletes striving for peak performance.
I earned my Doctor of Pharmacy degree from Midwestern University Chicago College of Pharmacy and a Bachelor of Science in Biochemistry from the University of Florida. Over the years, I’ve held leadership roles in clinical pharmacy, hospital medicine, and infectious disease management, gaining invaluable experience in both conventional and integrative care.
At the core of my work is a deep belief: chronic illness is not a life sentence—it’s a challenge that can be reversed with the right approach. Whether through advanced IV therapies, microbiome optimization, or personalized health protocols, my goal is to empower people to reclaim their health, achieve longevity, and experience the future of medicine today.

Director of Peptide Medicine

Jimmy Ryan, PhD

Director of Transcriptomics

Scientific Leadership